Sichuan Xieli Pharmaceutical Co., Ltd. was founded in 1980. Over the past 40 years, it has always adhered to the mission of "Joint Together to Create a Healthy Career", focusing on the pharmaceutical and health industry, and is committed to the R&D, production and sales of natural active ingredient extraction and its derivatives, as well as characteristic fully synthetic APIs.
The company holds 28 national drug registration approvals. Its products have completed drug registration for more than 40 varieties in over 100 countries around the world, covering multiple therapeutic areas such as cardiovascular and cerebrovascular diseases, and anti-tumor. The products are exported to nearly 50 countries and regions including Europe, the United States, and Japan, and the company has established stable cooperative relations with many Fortune 500 pharmaceutical enterprises, making it a trusted API supplier in the global pharmaceutical supply chain.
The company operates 3 major production bases, which strictly comply with international pharmaceuticals GMP standards and have obtained multiple international certifications, including those from the U.S. FDA, EU GMP, and Japanese GMP. Additionally, the company has built a robust EHS (Environment, Health, and Safety) management system and successfully passed the on-site audit of the Pharmaceutical Supply Chain Initiative (PSCI), practicing an operational philosophy centered on compliance, environmental friendliness, and sustainability.
While pursuing steady development, the company actively fulfills its social responsibilities by deeply engaging in targeted poverty alleviation and rural revitalization initiatives. It has been honored with titles such as "Advanced Collective for Pairing Assistance to Poor Counties in Tibetan and Yi Autonomous Areas" (awarded by the Sichuan Provincial Party Committee and Government), "Advanced Collective for Pairing Support to Tibetan Areas" (awarded by Chengdu Municipality), and "Model of Pairing Support and Cooperation" (awarded by Aba Tibetan and Qiang Autonomous Prefecture). The company has also been successively recognized as a National High-Tech Enterprise and one of China’s Top 100 Pharmaceutical Enterprises in Internationalization. Moreover, it has won awards including the Sichuan Provincial Science and Technology Progress Award, all of which demonstrate its outstanding innovation capabilities and industry influence.